Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 (currently amended). A composition, comprising:

from about 0.01 to about 5 percent by weight of hyaluronic acid, or a pharmaceutically acceptable salt thereof, having a molecular weight from about 1.6 to about ~~and~~ 2.2 million daltons;

from about 0.04 to about 15% by weight of a K60 to K100 polyvinylpyrrolidone; and

from about 86 to about 98% water,

wherein the viscosity of the composition is from about 50 to about 500 centipoise.

2 (original). The composition of claim 1, wherein the polyvinylpyrrolidone is from about K85 to about K95 and is from about 3 to about 10% by weight of the composition.

3 (original). The composition of claim 2, wherein the polyvinylpyrrolidone is from about 7 to about 10% by weight of the composition.

4 (currently amended). A ~~The~~ composition, ~~of claim 1, wherein the hyaluronic acid, or the pharmaceutically acceptable salt thereof, is~~ comprising:

from about 0.01 to about 2 percent by weight of hyaluronic acid, or a pharmaceutically acceptable salt thereof, having a molecular weight from about 1.8 to about 2.0 million daltons, ~~and from about 0.01 to about 2% by weight of the composition and~~,

from about 0.04 to about 15% by weight of a K60 to K100 polyvinylpyrrolidone; and

from about 86 to about 98% water,

wherein the viscosity of the composition is from about 90 to about 1000 centipoise.

5 (original). The composition of claim 4, in the form of a gel.

6 (currently amended). A The composition, comprising: ~~of claim 3, wherein the~~

from about 0.01 to about 2 percent by weight of hyaluronic acid, or a ~~the~~ pharmaceutically acceptable salt thereof, having a molecular weight ~~is~~ from about 1.8 to about 2.0 million daltons, ~~and from about 0.01% to about 2% by weight of the composition, and~~

from about 7 to about 10% by weight of a K60 to K100 polyvinylpyrrolidone; and

from about 86 to about 98% water,

wherein the viscosity of the composition is from about 90 to about 1000 centipoise.

7 (original). The composition of claim 6, in the form of a gel.

8 (original). The composition of claim 1, further comprising a viscosity-increasing agent, surfactant, stabilizing agent/preservative, flavour, fragrance, sweetening agent, bioadhesive agent, or a co-solubilizer.

9 (original). The composition of claim 8, further comprising a cellulose derivative, acrylic or methacrylic acid polymer or copolymer, ethylene or propylene glycol, polyethoxylated hydrogenated castor oil, EDTA, sodium benzoate, sodium or potassium sorbate, dextrin, sodium saccharin, or aspartame.

10 (original). The composition of claim 1, further comprising an antibacterial agent, disinfectant agent, antifungal agent, analgesic, anti-inflammatory, emollient, or a local anesthetic.

11 (original). The composition of claim 1, further comprising glycyrrhetinic acid or a pharmaceutically acceptable salt thereof.

12 (original). A composition comprising:

from about 0.04 to about 5 percent by weight of hyaluronic acid, or a pharmaceutically acceptable salt thereof, with a molecular weight from about 1.6 to about 2.2 million daltons;

from about 0.08 to about 15% by weight of a K60 to K100 polyvinylpyrrolidone; and

from about 86 to about 98% water,

wherein the viscosity of the composition is from about 50 to about 500 centipoise.

13 (original). The composition of claim 12, wherein the polyvinylpyrrolidone is from about K85 to about K95, and is from about 6 to about 12% by weight of the composition.

14 (original). The composition of claim 13, wherein the polyvinylpyrrolidone is from about 8 to about 10% by weight of the composition.

15 (original). The composition of claim 12, wherein the hyaluronic acid, or the pharmaceutically acceptable salt thereof, is from about 1.8 to about 2.0 million daltons and from about 0.04 to about 2% by weight of the composition.

16 (original). The composition of claim 15, in the form of a gel.

17 (original). The composition of claim 14, wherein the hyaluronic acid, or the pharmaceutically acceptable salt thereof, is from about 1.8 to about 2.0 million daltons and from about 0.04 to about 2% by weight of the composition.

18 (original). The composition of claim 17, in the form of a gel.

19 (original). The composition of claim 12, further comprising a viscosity-increasing agent, surfactant, stabilizing agent/preservative, flavour, fragrance, sweetening agent, bioadhesive agent, or a co-solubilizer.

20 (original). The composition of claim 19, further comprising a cellulose derivative, acrylic or methacrylic acid polymer or copolymer, ethylene or propylene glycol, polyethoxylated hydrogenated castor oil, EDTA, sodium benzoate, sodium or potassium sorbate, dextrin, sodium saccharin, or aspartame.

21 (original). The composition of claim 12, further comprising an antibacterial agent, disinfectant agent, antifungal agent, analgesic, anti-inflammatory, emollient, or a local anesthetic.

22 (original). The composition of claim 12, further comprising glycyrrhetinic acid or a pharmaceutically acceptable salt thereof.

23 (original). A flexible packet comprising the composition of claim 12.

24 (original). The packet of claim 23, being a sealed pouch comprising from about 10 to about 30 milliliters of the composition.

25 (original). A composition comprising hyaluronic acid or a pharmaceutically acceptable salt thereof; glycyrrhetinic acid or a pharmaceutically acceptable salt thereof; and polyvinylpyrrolidone.

26 (original). A flexible packet comprising the composition of claim 25.

27 (original). The composition of claim 25, further comprising a viscosity-increasing agent, surfactant, stabilizing agent/preservative, flavour, fragrance, sweetening agent, bioadhesive agent, or a co-solubilizer.

28 (original). The composition of claim 27, further comprising a cellulose derivative, acrylic or methacrylic acid polymer or copolymer, ethylene or propylene glycol, polyethoxylated hydrogenated castor oil, EDTA, sodium benzoate, sodium or potassium sorbate, dextrin, sodium saccharin, or aspartame.

29 (original). The composition of claim 25, further comprising an antibacterial agent, disinfectant agent, antifungal agent, analgesic, anti-inflammatory, emollient, or a local anesthetic.

30 (original). A method for treating or preventing inflammation in a patient comprising:

administering to a patient in need thereof an effective amount of a composition comprising:

(i) from about 0.01 to about 5 percent by weight of hyaluronic acid, or a pharmaceutically acceptable salt thereof, having a molecular weight from about 1.6 to about 2.2 million daltons;

(ii) from about 0.04 to about 15% by weight of a K60 to K100 polyvinylpyrrolidone; and

(iii) from about 86 to about 98% water,

wherein the viscosity of the composition is from about 50 to about 500 centipoise.

31 (original). The method of claim 30, wherein the composition is administered at least twice daily for at least two consecutive days.

32 (original). The method of claim 30, wherein the composition is administered at least three times daily for at least four consecutive days.

33 (original). The method of claim 30, wherein the composition is administered at least three times daily for at least seven consecutive days.

34 (original). The method of claim 30, wherein the composition further comprises a viscosity-increasing agent, surfactant, stabilizing agent/preservative, flavour, fragrance, sweetening agent, bioadhesive agent, or a co-solubilizer.

35 (original). The method of claim 34, wherein the composition further comprises a cellulose derivative, acrylic or methacrylic acid polymer or copolymer, ethylene or propylene glycol, polyethoxylated hydrogenated castor oil, EDTA, sodium benzoate, sodium or potassium sorbate, dextrin, sodium saccharin, or aspartame.

36 (original). The method of claim 30, wherein the composition further comprises an antibacterial agent, disinfectant agent, antifungal agent, analgesic, anti-inflammatory, emollient, or a local anesthetic.

37 (original). The method of claim 30, wherein the administration is by topical application.

38 (original). The method of claim 30, wherein the composition further comprises glycyrrhetinic acid or a pharmaceutically acceptable salt thereof.

39 (original). A method for treating or preventing inflammation in a patient, comprising administering to a patient in need thereof an effective amount of a composition comprising

hyaluronic acid or a pharmaceutically acceptable salt thereof; glycyrrhetinic acid or a pharmaceutically acceptable salt thereof; and polyvinylpyrrolidone.

40 (original). The method of claim 39, wherein the administration is by topical application.

41 (original). The method of claim 39, wherein the composition is administered at least twice daily for at least two consecutive days.

42 (original). The method of claim 39, wherein the composition is administered at least three times daily for at least four consecutive days.

43 (original). The method of claim 39, wherein the composition is administered at least three times daily for at least seven consecutive days.

44 (original). The method of claim 39, wherein the composition further comprises a viscosity-increasing agent, surfactant, stabilizing agent/preservative, flavour, fragrance, sweetening agent, bioadhesive agent, or a co-solubilizer.

45 (original). The method of claim 44, wherein the composition further comprises a cellulose derivative, acrylic or methacrylic acid polymer or copolymer, ethylene or propylene glycol, polyethoxylated hydrogenated castor oil, EDTA, sodium benzoate, sodium or potassium sorbate, dextrin, sodium saccharin, or aspartame.

46 (original). The method of claim 39, wherein the composition further comprises an antibacterial agent, disinfectant agent, antifungal agent, analgesic, anti-inflammatory, emollient, or a local anesthetic.

47 (currently amended). A method for treating or preventing inflammation in the oral cavity of a patient comprising:

administering to the oral cavity of ~~having~~ a patient in need thereof ~~gargle~~ an effective amount of a composition comprising:

(i) from about 0.01 to about 5 percent by weight of hyaluronic acid, or a pharmaceutically acceptable salt thereof, having a molecular weight from about 1.6 to about 2.2 million daltons;

(ii) from about 0.04 to about 15% by weight of a K60 to K100 polyvinylpyrrolidone; and

(iii) from about 86 to about 98% water,

wherein the viscosity of the composition is from about 50 to about 500 centipoise.

48 (currently amended). A method for treating or preventing inflammation in the oral cavity of a patient comprising:

administering to the oral cavity of a ~~having~~ a patient in need thereof ~~gargle~~ an effective amount of a composition comprising hyaluronic acid or a pharmaceutically acceptable salt thereof; glycyrrhetinic acid or a pharmaceutically acceptable salt thereof; and polyvinylpyrrolidone.

49 (currently amended). The method of claim 81 ~~47 or 48~~, wherein the patient gargles the composition at least twice daily for at least two consecutive days.

50 (currently amended). The method of claim 81 ~~47 or 48~~, wherein the patient gargles the composition at least three times daily for at least four consecutive days.

51 (currently amended). The method of claim 81 ~~47 or 48~~, wherein the patient gargles the composition at least three times daily for at least seven consecutive days.

52 (original). The method of claim 47, wherein the composition further comprises glycyrrhetinic acid or a pharmaceutically acceptable salt thereof.

53 (currently amended). The method of claim 81 ~~47 or 48~~, wherein the patient avoids eating or drinking for at least one hour after gargling.

54 (original). A method for treating or preventing mucositis in a patient comprising:

administering to a patient in need thereof an effective amount of a composition comprising:

(i) from about 0.01 to about 5 percent by weight of hyaluronic acid, or a pharmaceutically acceptable salt thereof, having a molecular weight from about 1.6 to about 2.2 million daltons;

(ii) from about 0.04 to about 15% by weight of a K60 to K100 polyvinylpyrrolidone; and

(iii) from about 86 to about 98% water,

wherein the viscosity of the composition is from about 50 to about 500 centipoise.

55 (original). A method for treating or preventing mucositis in a patient comprising:

administering to a patient in need thereof an effective amount of a composition comprising hyaluronic acid or a pharmaceutically acceptable salt thereof; glycyrrhetinic acid or a pharmaceutically acceptable salt thereof; and polyvinylpyrrolidone.

56 (original). The method of claim 54 or 55, wherein the composition is administered at least twice daily for at least two consecutive days.

57 (original). The method of claim 54 or 55, wherein the composition is administered at least three times daily for at least four consecutive days.

58 (original). The method of claim 54 or 55, wherein the composition is administered at least three times daily for at least seven consecutive days.

59 (original). The method of claim 54, wherein the composition further comprises glycyrrhetinic acid or a pharmaceutically acceptable salt thereof.

60 (original). A method for treating pain resulting from oral surgery in a patient in need thereof comprising:

having a patient in need thereof gargle an effective amount of a composition comprising:

(i) from about 0.01 to about 5 percent by weight of hyaluronic acid, or a pharmaceutically acceptable salt thereof, having a molecular weight from about 1.6 to about 2.2 million daltons;

(ii) from about 0.04 to about 15% by weight of a K60 to K100 polyvinylpyrrolidone; and

(iii) from about 86 to about 98% water,

wherein the viscosity of the composition is from about 50 to about 500 centipoise.

61 (original). A method for treating pain resulting from oral surgery in a patient in need thereof comprising:

having a patient in need thereof gargle an effective amount of a composition comprising hyaluronic acid or a pharmaceutically acceptable salt thereof; glycyrrhetinic acid or a pharmaceutically acceptable salt thereof; and polyvinylpyrrolidone.

62 (original). The method of claim 60 or 61, wherein the patient gargles the composition at least twice daily for at least two consecutive days.

63 (original). The method of claim 60 or 61, wherein the patient gargles the composition at least three times daily for at least four consecutive days.

64 (original). The method of claim 60 or 61, wherein the patient gargles the composition at least three times daily for at least seven consecutive days.

65 (original). The method of claim 60, wherein the composition further comprises glycyrrhetinic acid or a pharmaceutically acceptable salt thereof.

66 (new). A composition, comprising about 0.1% by weight sodium hyaluronate, about 0.06% by weight glycyrrhetinic acid, about 9.0 % by weight PVP (K60 to K100), about 6.0% by

weight maltodextrin, about 2.94% by weight propylene glycol, about 0.3 % by weight potassium sorbate, about 0.3 % by weight sodium benzoate, about 1.5 % by weight hydroxyethyl cellulose, about 0.27 % by weight hydrogenated castor oil PEG-40, about 0.1 % by weight disodium EDTA, about 0.5 % by weight benzalkonium chloride, about 0.16% by weight perfume, about 0.1% by weight sodium saccharin, and about 78.44% by weight water.

67 (new). A method for treating or preventing inflammation in a patient comprising administering to a patient in need thereof an effective amount of the composition of claim 66.

68 (new). A method for treating or preventing inflammation in the oral cavity of a patient comprising administering to the oral cavity of a patient in need thereof an effective amount of the composition of claim 66.

69 (new). A method for treating or preventing mucositis in a patient comprising administering to a patient in need thereof an effective amount of the composition of claim 66.

70 (new). A method for treating pain resulting from oral surgery in a patient in need thereof comprising having a patient in need thereof gargle an effective amount of the composition of claim 66.

71 (new). The composition of claim 1, 4, 6 or 12, wherein the viscosity is measured using a Brookfield Model DV1+ viscometer at 22°-25°C, or using a Haake Model VT02 viscometer at 22°-25°C.

72 (new). The method of claim 30, 47, 54 or 60, wherein the viscosity is measured using a Brookfield Model DV1+ viscometer at 22°-25°C, or using a Haake Model VT02 viscometer at 22°-25°C.

73 (new). The method of claim 30, 39 or 67, wherein the inflammation is mucositis, stomatitis or an aphthous ulcer.

74 (new). The method of claim 30, 39 or 67, wherein the inflammation occurs in the oral cavity.

75 (new). The method of claim 30, 39 or 67, wherein the inflammation occurs in the oro-pharynx.

76 (new). The method of claim 30, 39 or 67, wherein the inflammation occurs in the oesophagus.

77 (new). The method of claim 30, 39 or 67, wherein the inflammation occurs in the vagina.

78 (new). The method of claim 30, 39 or 67, wherein the inflammation occurs in the rectum.

79 (new). The method of claim 30, 39 or 67, wherein the patient has Behcet's syndrome.

80 (new). The method of claim 47, 48 or 68, wherein the inflammation is mucositis, stomatitis or an aphthous ulcer.

81 (new). The method of claim 47, 48 or 68, wherein administering comprises gargling the composition.

82 (new). The method of claim 47, 48 or 68, wherein the inflammation is caused by a post-traumatic lesion, lichen planus, radiotherapy-induced stomatitis or leukoplakia.

83 (new). The method of claim 54, 55 or 69, wherein the mucositis occurs in the oral cavity.

84 (new). The method of claim 54, 55 or 69, wherein the mucositis occurs in the oro-pharynx.

85 (new). The method of claim 54, 55 or 69, wherein the mucositis occurs in the oesophagus.

86 (new). The method of claim 54, 55 or 69, wherein the mucositis occurs in the vagina.

87 (new). The method of claim 54, 55 or 69, wherein the mucositis occurs in the rectum.

88 (new). The method of claim 54, 55 or 69, wherein the patient has Behcet's syndrome.